Evommune Licenses EVO570 for $30 Million Upfront

Evommune obtained worldwide rights outside Greater China to develop, manufacture and commercialize EVO570, paying Hinova $20 million in cash and $10 million in pre-funded warrants. Hinova is eligible for up to approximately $1.1 billion in milestones and tiered royalties.